A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.

ABSTRACT: CD19-directed chimeric antigen receptor (CAR) T cells have yielded impressive response rates in refractory/relapse B cell acute lymphoblastic leukemia (B-ALL); however, most patients ultimately relapse due to poor CAR T cell persistence or resistance of either CD19⁺ or CD19^- B-ALL clones. CD22 is a pan-B marker whose expression is maintained in both CD19⁺ and CD19^- relapses. CD22-CAR T cells have been clinically used in B-ALL patients, although relapse also occurs. T cells engineered with a tandem CAR (Tan-CAR) containing in a single construct both CD19 and CD22 scFvs may be advantageous in achieving higher remission rates and/or preventing antigen loss. We have generated and functionally validated using cutting-edge assays a 4-1BB-based CD22/CD1

SUBMITTER: Zanetti SR 

PROVIDER: S-EPMC8821938 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature